The Activin Receptor Type 1 pipeline drugs market research report outlays comprehensive information on the Activin Receptor Type 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Activin Receptor Type 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Musculoskeletal Disorders, Hematological Disorders, Oncology, and Toxicology which include the indications Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Bone Disorders, Iron Deficiency Anemia, Anemia, Myelofibrosis, Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Chemotherapy Induced Anemia. It also reviews key players involved in Activin Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Activin Receptor Type 1 pipeline targets constitutes close to 14 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, IND/ CTA Filed, and Preclinical stages are 1, 2, 1, and 8 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Activin Receptor Type 1 overview
Activin A receptor type I (ACVR1) is a protein is encoded by the ACVR1 gene. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. It acts as a receptor for activin. It is involved for left-right pattern formation during embryogenesis.
For a complete picture of Activin Receptor Type 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
